Related Experiment Video
Updated: Jun 15, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Cognitive function and anticoagulation control in patients with atrial fibrillation
Greg C Flaker1, Janice Pogue, Salim Yusuf
1University of Missouri-Columbia, USA. flakerg@health.missouri.edu <flakerg@health.missouri.edu>
Circulation. Cardiovascular Quality and Outcomes
|March 18, 2010
Summary
Cognitive dysfunction in atrial fibrillation patients is linked to poorer anticoagulation and increased risks. Improving anticoagulation management can reduce vascular events and bleeding in these individuals.
Area of Science:
- Cardiology
- Geriatrics
- Neurology
Background:
- Elderly patients with atrial fibrillation often experience cognitive dysfunction.
- This cognitive impairment can lead to less effective oral anticoagulation.
- Consequently, these patients face higher risks of vascular events and bleeding.
Purpose of the Study:
- To investigate the association between cognitive function and anticoagulation control in atrial fibrillation patients.
- To determine if cognitive impairment predicts poor time in therapeutic range (TTR).
- To assess the impact of cognitive status on vascular events and bleeding.
Main Methods:
- Analysis of cognitive function using the Mini-Mental State Examination (MMSE) in 2510 atrial fibrillation patients.
- Correlation of MMSE scores with time in therapeutic range (TTR) for oral anticoagulation.
- Comparison of vascular events and bleeding rates based on MMSE scores.
Main Results:
- A significant percentage of patients (6.8%) showed scores indicative of dementia (MMSE <24), and 7.7% had intermediate scores (24-25).
- Lower MMSE scores, even mild impairment, correlated with reduced TTR (<65%).
- Patients with MMSE <26 experienced more vascular events and bleeding, but this risk diminished after controlling for TTR.
Conclusions:
- Cognitive dysfunction is prevalent in elderly atrial fibrillation patients, impacting anticoagulation effectiveness.
- The MMSE can identify patients needing enhanced anticoagulation management to improve outcomes.
- Optimizing anticoagulation in patients with cognitive impairment may reduce vascular events and bleeding.
More Related Videos
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...